← Back to Home

Revealing Cancer Cells’ Recognition Cues: Blocking ERAP1 Restores T-Cell Recognition of Mutant p53

Even when cancer cells carry mutations that could make them targets for immune attack, they may erase the recognition cues during protein processing. A new study reversed one such hiding mechanism in the laboratory, pointing toward ways to improve tumor antigen presentation, but its application to patient treatment still requires validation.

By SURL BioNews

To attack cancer cells, T cells must first find recognition cues on their surfaces. Even when a tumor carries a clear cancer-driving mutation, these cues may not appear. A new study found that blocking the protein-processing enzyme ERAP1 allows T cells to recognize cancer cells carrying a specific p53 mutation again. This laboratory finding directs efforts to improve immunotherapy toward how cancer cells display their own antigens.

The study, highlighted by Harvard Medical School on October 9, involved Dana-Farber Cancer Institute and other institutions. Its first author is Koji Haratani, and the paper was published in *Immunity* on September 17. The research focused on the tumor suppressor protein p53: mutations in its gene, TP53, often arise early in tumor evolution and are passed on to subsequent cancer cells, making them attractive targets for immunotherapy. However, identifying a mutation in a gene sequence is only the starting point for identifying a target.

T cells cannot directly read cancer cells’ DNA. Instead, they inspect short peptides carried by HLA molecules and displayed on the cell surface. Using ultrasensitive mass spectrometry to analyze the fragments actually presented, the research team clearly detected only 5 of 175 candidate wild-type p53 peptides predicted to bind to the relevant HLA molecules. This gap underscores the need to confirm whether cells actually process and display computationally predicted candidate targets.

p53 carrying the I195F mutation provided an example of a mechanism that could be reversed. The study found that this mutation can produce an immune recognition fragment containing 11 amino acids that binds to HLA-A*02:01 with high affinity. However, elevated ERAP1 activity in cancer cells overtrims the fragment, preventing its presentation. When researchers deleted ERAP1 or blocked its activity with an inhibitor, p53-targeting T cells regained their ability to recognize these cancer cells.

Other hiding mechanisms may not be resolved by the same approach. Many p53 mutation hotspots lie in regions that are difficult to process into antigens; some clinical tumors also lack the HLA alleles needed to present the relevant fragments. A peptide produced by another mutation, R175H, forms an unstable, short-lived complex with HLA, limiting T-cell activation and cancer-cell killing even when paired with a sensitive T-cell receptor. Whether a target appears and how long it remains both affect the effectiveness of an immune attack.

Based on these findings, the research team proposed a strategy to change the mix of peptides on tumor surfaces, hoping to provide the immune system with more recognizable targets that could potentially be combined with existing immunotherapies in the future. However, Dana-Farber explicitly stated that the study has not yet demonstrated that drugs can turn “cold tumors,” which elicit insufficient immune responses, into “hot tumors” in patients. The most concrete advance so far is the laboratory reversal of a specific antigen-hiding mechanism caused by ERAP1. Whether this can be safely applied in humans, and how much it might improve treatment responses, still requires further research.

References

  1. Harvard Medical School
  2. Dana-Farber Cancer Institute
  3. PubMed / Immunity